Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 601-608

  Kvols, Larry K ^a   Woltering, Eugene A ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Octreotide; Solid tumors; SOM230; Somatostatin

Indexed keywords

ANGIOPEPTIN; ANTIESTROGEN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; GROWTH FACTOR; HORMONE ANTAGONIST; METHOTREXATE; MITOMYCIN C; OCTREOTIDE; PACLITAXEL; PASIREOTIDE; PENTETREOTIDE; PROLACTIN ANTAGONIST; QUINAGOLIDE; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SURAMIN; TAMOXIFEN; UNCLASSIFIED DRUG; VAPREOTIDE; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CELL SURFACE; CHOLELITHIASIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; IMMUNOMODULATION; LIVER CANCER; LIVER TOXICITY; METABOLIC DISORDER; MONOTHERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; SUSTAINED RELEASE PREPARATION; TUMOR CELL; TUMOR VOLUME;

HUMANS; NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 33747615699     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000210335.95828.ed     Document Type: Review

References (94)

1. Oberg K, Kvols L, Caplin M, Delle FG, De Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15:966-973.
2. Fajans SS, Vinik AI. Insulin-producing islet cell tumors. Endocrinol Metab Clin North Am 1989; 18:45-74.
3. Long RG, Bryant MG, Mitchell SJ, Adrian TE, Polak JM, Bloom SR. Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas). Br Med J (Clin Res Ed) 1981; 282:1767-1771.
4. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663-666.
5. Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, et al. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Horm Metab Res Suppl 1993; 27:24-27.
6. di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402-408.
7. Soga J, Yakuwa Y. Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17:389-400.
8. Angeletti S, Corleto VD, Schillaci O, Moretti A, Panzuto F, Annibale B, et al. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours. Ital J Gastroenterol Hepatol 1999; 31:23-27.
9. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors. Digestion 1999; 60 (Suppl 2):9-14.
10. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999; 10 (Suppl 2):S31-S38.
11. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600-606.
12. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 (Suppl 1):84-91.
13. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol 2001; 12 (Suppl 2):S105-S109.
14. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5:1502-1522.
15. Wass JA, Popovic V, Chayvialle JA. Proceedings of the discussion, "Tolerability and safety of Sandostatin". Metabolism 1992; 41:80-82.
16. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997; 82:23-28.
17. Mangupli R, Lisette A, Ivett C, Paul C, de IR V, Luis CJ. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003; 6:29-34.
18. Gorden P, Comi RJ, Maton PN, Go VL. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110:35-50.
19. Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 1993; 32:197-201.
20. Pape UF, Wiedenmann B. Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev 2003; 29:565-569.
21. Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997; 75:798-803.
22. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998; 93:1468-1471.
23. Goldberg RM, Moertel CG, Wieand HS, Krook JE, Schutt AJ, Veeder MH, et al. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic. Cancer 1995; 76:961-966.
24. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217:143-152.
25. Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000; 85:983-988.
26. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-716.
27. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001; 47 (Suppl 2):1-29.
28. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133-1140.
29. Pawlikowski M, Melen-Mucha G. Perspectives of new potential therapeutic applications of somatostatin analogs. Neuro Endocrinol Lett 2003; 24:21-27.
30. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989; 49:7002-7009.
31. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43:27-35.
32. 2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56:1823-1827.
33. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275:7862-7869.
34. Pawlikowski M, Kunert-Radek J, Stepien H. Somatostatin - an antiproliferative hormone. In: Dohler KD, Pawlikowski M, editors. Progress in Neuropeptide Research. Switzerland: Birkauser Verlag, Basel; 1989. pp. 246-269.
35. Redding TW, Schally AV. Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci U S A 1983; 80:1078-1082.
36. Reubi JC. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol (Copenh) 1985; 109:108-114.
37. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A 1994; 91:2315-2319.
38. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997; 9:193-204.
39. Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A 1997; 94:9343-9348.
40. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002; 66:161-183.
41. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217:143-152.
42. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol 1997; 36:607-614.
43. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-147.
44. Watson JC, Gebhardt BM, Alperin-Lea RC, Redmann JG, Woltering EA. Initiation of kdr gene transcription is associated with conversion of human vascular endothelium to an angiogenic phenotype. Surg Forum 1996; XLVII:462-464.
45. Danesi R, Del Tacca M. The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996; 45:49-50.
46. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997; 3:265-272.
47. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15:77-86.
48. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J. Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000; 268:567-571.
49. Treiber G, Wex T, Malfertheiner P. Inhibition of angiogenesis rather than growth hormones is a key factor for ocreotide treatment response in HCC patients. Am Soc Clin Oncol 2004; absts 91.
50. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996; 23:455-464.
51. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12:450-482.
52. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001; 47 (Suppl 2):30-39.
53. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034-3040.
54. Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989; 9:889-891.
55. Macaulay VM, Smith IE, Everard MJ, Teale JD, Reubi JC, Millar JL. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 1991; 64:451-456.
56. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001; 86:5729-5736.
57. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol 2002; 24:440-446.
58. Luo Q, Peyman GA, Conway MD, Woltering EA. Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996; 15:909-913.
59. Anthony L, Johnson D, Hande K, Shaff M, Winn S, Krozely M, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol 1993; 32:217-223.
60. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. World J Gastroenterol 2005; 11:2041-2044.
61. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42:442-447.
62. Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, et al. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62:627-630.
63. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002; 87:4142-4146.
64. Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Valles J, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. 2004; 56:471-476.
65. Rivera JA, Alturaihi H, Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog 2005; 4:10.
66. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005; 78:69-80.
67. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002; 49:1245-1250.
68. Fisher WE, Muscarella P, O'Dorisio TM, O'Dorisio MS, Kim JA, Doran TA, et al. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 1996; 120:234-240.
69. Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8:540-545.
70. Ebert M, Friess H, Beger HG, Buchler MW. Role of octreotide in the treatment of pancreatic cancer. Digestion 1994; 55 (Suppl 1):48-51.
71. Reichlin S. Somatostatin. N Engl J Med 1983; 309:1495-1501.
72. Reichlin S. Somatostatin (second of two parts). N Engl J Med 1983; 309:1556-1563.
73. Reubi JC, Waser B, Foekens JA, Klijn JG, Lamberts SW, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer 1990; 46:416-420.
74. Weber C, Merriam L, Koschitzky T, Karp F, Benson M, Forde K, et al. Inhibition of growth of human breast carcinomas in vivo by somatostatin analog SMS 201-995: treatment of nude mouse xenografts. Surgery 1989; 106:416-422.
75. Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res 1994; 54:6334-6337.
76. Weckbecker G, Tolcsvai L, Liu R, Bruns C. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 1992; 41:99-103.
77. Bontenbal M, Foekens JA, Lamberts SW, de Jong FH, van Putten WL, Braun HJ, et al. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Br J Cancer 1998; 77:115-122.
78. Nagasue N, Yu L, Yukaya H, Kohno H, Nakamura T. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 1995; 82:542-547.
79. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000; 95:218-222.
80. Villa E, Grottola A, Colantoni A, De Maria N, Buttafoco P, Ferretti I, et al. Hepatocellular carcinoma: role of estrogen receptors in the liver. Ann N Y Acad Sci 2002; 963:37-45.
81. Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45:766-774.
82. Pan DY, Qiao JG, Chen JW, Huo YC, Zhou YK, Shi HA. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. Hepatobiliary Pancreat Dis Int 2003; 2:211-215.
83. Vainas G, Pasaitou V, Galaktidou G, Maris K, Christodoulou K, Constantinidis C, et al. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. J Exp Clin Cancer Res 1997; 16:119-126.
84. Weckbecker G, Raulf F, Tolcsvai L, Bruns C. Potentiation of the antiproliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 1996; 57 (Suppl 1):22-28.
85. Lamberts SW, van Koetsveld P, Hofland LJ. The interrelationship between the anti-mitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin. Int J Cancer 1991; 48:938-941.
86. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology 1994; 51:70-73.
87. El Salhy M, Dennerqvist V. Effects of triple therapy with octreotide, galanin and serotonin on liver metastasis of human colon cancer in xenografts. Oncol Rep 2004; 11:1177-1182.
88. Melen-Mucha G, Winczyk K, Pawlikowski M. Effects of somatostatin analogs octreotide and lanreotide on the proliferation and apoptosis in colon 38 tumor: interaction with 5-fluorouracil. Neuroendocrinol Lett 2000; 21:137-142.
89. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 19:8-12.
90. Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, et al. Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Can Res Clin Oncol 2003; 129:327-334.
91. Schulz S, Schmitt J, Weise W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol 2003; 89:385-390.
92. Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, et al. Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Am J Obstet Gynecol 1999; 181:583-590.
93. 5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28:836-846.
94. Witzig TE, Letendre L, Gerstner J, Schroeder G, Mailliard JA, Colon-Otero G, et al. Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial. J Clin Oncol 1995; 13:2012-2015.